Prevention by theophylline of beta-2-receptor down regulation in healthy subjects

  • Michiel G. M. Derks
  • Richard P. Koopmans
  • Els Oosterhoff
  • Chris J. van Boxtel
Article

Summary

Adrenergic down-regulation can occur rapidly in many tissues. Therefore β2-agonists might have a rapidly decreasing effect in time, which is a potential problem for the treatment of bronchial asthma. Thisin vivo study tested the hypothesis that theophyline can prevent adrenergic down-regulation. A randomised, double blind, placebo-controlled cross-over study was performed in eight healthy subjects. Terbutaline concentration-effect relationships were studied before and after one week of dosing of terbutaline, with or without theophylline. Slow-release terbutaline 5 mg daily was administered for 7 days in combination with either placebo or slow-release theophylline. Concentration-effect relationships of terbutaline after a single subcutaneous injection were studied before and after the 7 day terbutaline treatment. Eosinopenia and hypokalemia were the systemic effect parameters. Terbutaline concentration-time courses were described with a two-compartment model and those of theophylline with a polynomial equation. A hypothetical effect compartment model was applied to link terbutaline plasma concentration via an Emax model to the studied effects. The interaction of theophylline and terbutaline was described with a non-competitive pharmacodynamic model. After one week of oral terbutaline, the mean EC50 (ng/L) of terbutaline increased for the eosinopenia from 1.87±1.66 to 3.78±2.18 (+102%) (p=0.012) with placebo, and to 2.73±1.99 (+46%) (p=0.025) with theophylline; for the hypokalemia the EC50 increased from 4.70±2.91 to 8.52±7.26 (+81%) (p=0.012) with placebo, and to 5.64+2.59 (+20%) (p=0.16) with theophylline. The results indicate that the non-specific phosphodiesterase inhibitor theophylline can prevent terbutaline-induced adrenergic down-regulation to a substantial degree.

Keywords

Theophylline beta-2-agonist healthy volunteer in vivo receptor down regulation PK/PD modelling 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Barnes PJ. Beta-adrenoceptors on smooth muscle, nerves and inflammatory cells. Life Sci 1993; 52: 2101–2109.CrossRefPubMedGoogle Scholar
  2. 2.
    Morandini R, Ghanem G, Portier-Lemarie A, Robaye B, Renaud A, Boeynaems JM. Action of cAMP on expression and release of adhesion molecules in human endothelial cells. American Journal of Physiology 110196; 270: H807–H816.Google Scholar
  3. 3.
    Chan SC, Li SH, Hanifin JM. Increased interleukin-4 production by atopic mononuclear leukocytes correlates with increased cyclic adenosine monophosphate-phosphodiesterase activity and is reversible by phosphodiesterase inhibition. Journal of Investigative Dermatology 1993; 100: 681–684.CrossRefPubMedGoogle Scholar
  4. 4.
    Laitinen LA, Laitinen A, Haahtela T. A comparative study of the effects of an inhaled corticosteroid, budesonide, and a beta-2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: a randomized, double- blind, parallel-group controlled trial. J Allergy Clin Immunol. 1992; 90: 32–42.CrossRefPubMedGoogle Scholar
  5. 5.
    Krouwels FH, Hol BA, Lutter R, et al. Histamine affects interleukin-4, interleukin-5, and interferon-gamma production by human T cell clones from the airways and blood. American Journal of Respiratory Cell & Moleculur Biology 1998; 18: 721–730.Google Scholar
  6. 6.
    al-Essa LY, Niwa M, Kohno K, Nozaki M, Tsurumi K. Heterogeneity of circulating and exudated polymorphonuclear leukocytes in superoxide-generating response to cyclic AMP and cyclic AMP-elevating agents. Investigation of the underlying mechanism. Biochemical Pharmacology 1995; 49: 315–322.CrossRefPubMedGoogle Scholar
  7. 7.
    Barnes PJ. Beta-adrenergic receptors and their regulation. American Journal of Respiratory & Criticall Care Medicine 1995; 152: 838–860.Google Scholar
  8. 8.
    Giembycz MA. Phosphodiesterase 4 and tolerance to β2-agonists in asthma. TiPS 1996; 17: 331–336.PubMedGoogle Scholar
  9. 9.
    McGraw DW Donnelly ET, Eason MG, Green SA, Liggett SB. Role of beta ARK in long-term agonist-promoted desensitisation of the beta 2-adrenergic receptor. Cellular Signalling 1998; 10: 197–204.CrossRefPubMedGoogle Scholar
  10. 10.
    Conti M., Monaco L, Geremia R, Stefanini M. Effect of phosphodiesterase inhibitors on Sertoli cell refractoriness: reversal of the impaired aromatization. Endocrinology 1986; 118: 901–908.CrossRefPubMedGoogle Scholar
  11. 11.
    Houslay MD, Griffiths SL, Horton YM, et al. Regulation of intracellular cyclic AMP concentration of adenylyl cyclase coupled with the action and activation of specific isoforms of cyclic AMP phosphodiesterase. Biochemical Society Transactions 1992; 20: 140–146.PubMedGoogle Scholar
  12. 12.
    Ashby B. Model of prostaglandin-regulated cyclic AMP metabolism in intact platelets: Examination of time-dependent effects on adenylate cyclase and phosphodiesterase activities. Molecular Pharmacology 1989; 36:Google Scholar
  13. 13.
    Nielson CP, Vestal RE, Sturm RJ, Heaslip R. Effects of selective phosphodiesterase inhibitors on the polymorphonuclear leukocyte respiratory burst. Journal of Allergy & Clinical Immunology 1990; 86: 801–808.CrossRefGoogle Scholar
  14. 14.
    Torphy TJ, Zhou HL, Cieslinski LB, Stimulation of beta adrenoceptors in a human monocyte cell line (U937) up-regulates cyclic AMP-specific phosphodiesterase activity. Journal of Pharmacology & Experimental Therapeutics 1992; 263: 1195–1205Google Scholar
  15. 15.
    Lipworth BJ. Airway subsensitivity with long-acting beta 2-agonists. Is there cause for concern? Drug Safety 1997; 16: 295–308.CrossRefPubMedGoogle Scholar
  16. 16.
    Grove A, Lipworth BJ. Tolerance with beta 2-adrenoceptor agonists: time for reappraisal. Br J clin Pharmac 1995; 39: 109–118.Google Scholar
  17. 17.
    Hayes MJ, Qing F, Rhodes CG, et al. In vivo quantification of human pulmonary beta-adrenoceptors: effect of beta-agonist therapy. American Journal of Respiratory & Critical Care Medicine 1996: 154: 1277–1283.Google Scholar
  18. 18.
    Jonkers RE, Braat MCP, Koopmans RP, et al. Pharmacodynamic modelling of the drug-induced downregulation of a beta(2)-adrenoceptor mediated response and lack of restoration of receptor function after a single high dose of prednisone. European Journal of Clinical Pharmacology 1995; 49: 37–44.CrossRefPubMedGoogle Scholar
  19. 19.
    Lemoine H, Overlack C. Highly potent beta-2 sympathomimetics convert to less potent partial agonists as relaxants of guinea pig tracheae maximally contracted by carbachol. Comparison of relaxation with receptor binding and adenylate cyclase stimulation. J Pharmacol Exp Ther 1992; 261: 258–270.PubMedGoogle Scholar
  20. 20.
    Cheung D, Wever AM, de Goeij JA, de Graaf CS, Steen H, Sterk PJ. Effects of theophylline on tolerance to the bronchoprotective actions of salmeterol in vivo. American Journal of Respiratory & Critical Care Medicine 1998; 158: 792–796.Google Scholar
  21. 21.
    Torphy TJ, Zhou HL, Foley JJ, Sarau HM, Manning CD, Barnette MS. Salbutanol up-regulates PDE4 activity and induces a heterologous desensitization of U937 cells to prostaglandin E2. Implications for the therapeutic use of beta-adrenoceptor agonists. Journal of Biological Chemistry 1995; 270: 23598–23604.CrossRefPubMedGoogle Scholar
  22. 22.
    Bousquet-Melou A, Galitzky J, Moreno CM, Berlan M, Lafontan M. Desensitization of beta-adrenergic responses in adipocytes involves receptor subtypes and cAMP phosphodiesterase. European Journal of Pharmacology 1995; 289: 235–247.CrossRefPubMedGoogle Scholar
  23. 23.
    Tanizawa M, Watanabe T, Kume H, Yamaki K, Miyamoto K, Takagi K. Phosphodiesterase IV inhibitors synergistically potentiate relaxation induced by forskolin in guinea-pig trachea. Clinical & Experimental Pharmacology & Physiology 1998; 25: 114–119.CrossRefGoogle Scholar
  24. 24.
    Au BT, Teixeira MM, Collins PD, Williams TJ. Effect of PDE4 inhibitors on zymosan-induced IL-8 release from human neutrophils: synergism with prostanoids and salbutamol. British Journal of Pharmacology 1998; 123: 1260–1266.CrossRefPubMedGoogle Scholar
  25. 25.
    Wrenn K, Slovis CM, Murphy F, Greenberg RS. Aminophylline therapy for acute bronchospastic disease in the emergency room. Ann Intern Med 1991; 115: 241–247.PubMedGoogle Scholar
  26. 26.
    Kidney JC, Dominguez M, Taylor P, et al. Withdrawing chronic theophylline treatment causes immunomodulation in the blood of asthmatic patients. Thorax 1994; 49: 396.Google Scholar
  27. 27.
    Kidney JC, Dominguez M, Taylor R, Rose M, Chung KF, Barnes PJ. Immunomodulation by theophylline in asthma. Am J Respir Crit Care Med 1995; 151: 1907–14.PubMedGoogle Scholar
  28. 28.
    Kidney J, Dominguez M, Taylor PM, Rose M, Chung KF, Barnes PJ. Immunomodulation by theophylline in asthma. Demonstration by withdrawal of therapy. American Journal of Respiratory & Critical Care Medicine 1995; 151: 1907–1914.Google Scholar
  29. 29.
    Brenner M, Berkowitz R, Marshall N, Strunk RC. Need for theophylline in severe steroid-requiring asthmatics. Clin Allergy 1988; 18: 143–150.CrossRefPubMedGoogle Scholar
  30. 30.
    Nassif EG, Weinberger M, Thompson R, Huntley W. The value of maintenance theophylline in steroid-dependent asthma. New England Journal of Medicine 1981; 304: 71–75.CrossRefPubMedGoogle Scholar
  31. 31.
    van den Berg BT, Braat MC, Koolen MG, van Boxtel CJ. PK/PD modelling of the combined eosinopenic effects of formoterol and theophylline in man. In: Danhof M, Peck CC, editors. Measurement and kinetics of in vivo drug effects; Advances in simultaneous pharmacokinetic/pharmacodynamic modelling. Leiden/Amsterdam Center for Drug Research, 1994: 73–74.Google Scholar
  32. 32.
    Haffner CA, Hughes B, Kendall MJ, Holder R. Pilot study to compare the bronchodilator and metabolic responses to terbutaline infusion in seven asthmatic subjects-are they correlated? Journal of Clinical Pharmacy & Therapeutics 1992; 17: 229–231.Google Scholar
  33. 33.
    Jenne JW, Chick TW, Strickland RD, Wall FJ. Subsensitivity of beta responses during therapy with a long-acting beta-2 preparation. Journal of Allergy & Clinical Immunology 1977; 59: 383–390.CrossRefGoogle Scholar
  34. 34.
    Jonkers RE, van Boxtel CJ, Oosterhuis B. Beta-2-adrenoceptormediated hypokalemia and its abolishment by oxprenolol. Clinical Pharmatology & Therapeutics 1987; 42: 627–633.CrossRefGoogle Scholar
  35. 35.
    Cooper MJ, Mirkin BL, Anders MW. A rapid micromethod for the high-performance liquid chromatographic determination of theophylline in human serum. Journal of Chromatography 1977; 143: 324–326.CrossRefPubMedGoogle Scholar
  36. 36.
    MicroMath, inc. Scientist (2.0). 1986. Salt Lake City, MicroMath Scientific Software.Google Scholar
  37. 37.
    Gibaldi M, Perrier D. Pharmacokinetics. New York: Marcel Dekker inc., 1975.Google Scholar
  38. 38.
    Holford NH, Sheiner LB. Understanding the Dose-Effect relationship: Clinical Application of Pharmacokinetic-Pharmacodynamic Modes. Clinical Pharmacokinetics 1981; 6: 429–453.CrossRefPubMedGoogle Scholar
  39. 39.
    Ariens EJ, Simonis AM. A molecular basis for drug action. J Pharm Pharmacol 1964; 16: 137–157.Google Scholar
  40. 40.
    van den Berg BTJ, Koolen MGJ, Braat MCP, van Boxtel CJ. Pharmacokinetic-pharmacodynamic interaction of formoterol and theophyline. Am J Respir Crit Care Med 1994; 149: A470.Google Scholar
  41. 41.
    Tan KS, McFarlane LC, Lipworth BJ. Concomitant administration of low-dose prednisolone protects against in vivo beta2-adrenoceptor subsensitivity induced by regular formoterol. Chest 1998; 113: 34–41.CrossRefPubMedGoogle Scholar
  42. 42.
    Tan KS, Grove A, McLean A, Gnosspelius Y, Hall IP, Lipworth BJ. Systemic corticosteriod rapidly reverses bronchodilator subsensitivity induced by formoterol in asthmatic patients. American Journal of Respiratory & Critical Care Medicine 1997; 156: 28–35.Google Scholar
  43. 43.
    Dent G, Magnussen H, Rabe KF. Cyclic Nucleotide Phosphodiesterases in the Human Lung. Lung 1994; 172: 129–146.CrossRefPubMedGoogle Scholar
  44. 44.
    Hatzelmann A, Tenor H, Schudt C, Differential effects of non-selective and selective phosphodiesterase inhibitors on human eosinophil functions. British Journal of Pharmacology 1995; 114: 821–831.PubMedGoogle Scholar
  45. 45.
    Santing RE, Olymulder CG, van der Molen K, Meurs H, Zaagsma J. Phosphodiesterase inhibitors reduce bronchial hyperreactivity and airway inflammation in unrestrained guinea pigs. European Journal of Pharmacology 1995; 275: 75–82.CrossRefPubMedGoogle Scholar
  46. 46.
    Barnette MS, Christensen SB, Essayan DM, et al. A potent and selective phosphodiesterase (PDE) IV inhibitor, suppresses activities of several immune and inflammatory cells. Am J Respir Crit Care Med 1994; 149: A209.Google Scholar
  47. 47.
    Moodley I, Mottin G, Perrin S, Junien JL, Lagente V. Effects of selective phosphodiesterase inhibitors and theophylline on antigeninduced microvascular leakage in the guinea-pig trachea. Am J Respir Crit Care Med 1994; 149: A328.Google Scholar
  48. 48.
    Sullivan P, Bekir S, Jaffar Z, Page C, Jeffery P, Costello J. Anti-inflammatory effects of low-dose oral theophylline in atopic asthma. Lancet 1994; 343: 1006–1008.CrossRefPubMedGoogle Scholar
  49. 49.
    Aziz I, Hall IP, McFarlane LC, Lipworth BJ. Beta2-adrenoceptor regulation and bronchodilator sensitivity after regular treatment with formoterol in subjects with stable asthma. Journal of Allergy & Clinical Immunology 1998; 101: 337–341.CrossRefGoogle Scholar
  50. 50.
    Pauwels RA, Lofdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. New England Journal of Medicine 1997; 337: 1405–1411.CrossRefPubMedGoogle Scholar
  51. 51.
    Evans DJ, Taylor DA, Zetterstrom O, Chung KF, O’Connor BJ, Barnes PJ. A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. New England Journal of Medicine 1997; 337: 1412–1418.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2000

Authors and Affiliations

  • Michiel G. M. Derks
    • 1
  • Richard P. Koopmans
    • 1
  • Els Oosterhoff
    • 1
  • Chris J. van Boxtel
    • 1
  1. 1.Department of Clinical Pharmacology & Pharmacotherapy, Academic Medical CenterThe University of AmsterdamAmsterdamThe Netherlands

Personalised recommendations